BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Puig I, Baylina M, Sánchez-delgado J, López-gongora S, Suarez D, García-iglesias P, Muñoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother 2016;71:2740-53. [DOI: 10.1093/jac/dkw220] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Li B, Lan X, Wang L, Zhao J, Ding J, Ding H, Lei J, Wei Y, Zhang W. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis. Microb Pathog 2020;142:104075. [PMID: 32074497 DOI: 10.1016/j.micpath.2020.104075] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in Special Patient Populations. Pharmacotherapy 2019;39:1012-22. [DOI: 10.1002/phar.2318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
3 Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, Bujanda L, Lucendo A, Jurecic NB, Perez-Lasala J, Shvets O, Fadeenko G, Huguet JM, Kikec Z, Bordin D, Voynovan I, Leja M, Machado JC, Areia M, Fernandez-Salazar L, Rodrigo L, Alekseenko S, Barrio J, Ortuño J, Perona M, Vologzhanina L, Romero PM, Zaytsev O, Rokkas T, Georgopoulos S, Pellicano R, Buzas GM, Modolell I, Gomez Rodriguez BJ, Simsek I, Simsek C, Lafuente MR, Ilchishina T, Camarero JG, Dominguez-Cajal M, Ntouli V, Dekhnich NN, Phull P, Nuñez O, Lerang F, Venerito M, Heluwaert F, Tonkic A, Caldas M, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol 2021;116:1220-9. [PMID: 33840725 DOI: 10.14309/ajg.0000000000001246] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Jung JH, Cho IK, Lee CH, Song GG, Lim JH. Clinical Outcomes of Standard Triple Therapy Plus Probiotics or Concomitant Therapy for Helicobacter pylori Infection. Gut Liver 2018;12:165-72. [PMID: 29212313 DOI: 10.5009/gnl17177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Dacoll C, Sánchez-delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay. Gastroenterología y Hepatología 2017;40:447-54. [DOI: 10.1016/j.gastrohep.2017.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Veliev AM, Maev IV, Andreev DN, Dicheva DT, Zaborovskii AV, Lobanova EG, Bektemirova LG. [The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease]. Ter Arkh 2019;91:28-33. [PMID: 32598751 DOI: 10.26442/00403660.2019.08.000382] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
8 Matsumoto H, Shiotani A, Graham DY. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol 2019;1149:211-25. [PMID: 31016626 DOI: 10.1007/5584_2019_367] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
9 O'Connor A, Lamarque D, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2017. Helicobacter 2017;22 Suppl 1. [PMID: 28891137 DOI: 10.1111/hel.12410] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
10 Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med 2019;8:E1498. [PMID: 31546909 DOI: 10.3390/jcm8091498] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
11 Kim JL, Cho SJ, Chung SJ, Lee A, Choi J, Chung H, Kim SG. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial. Clin Transl Gastroenterol 2020;11:e00194. [PMID: 33094958 DOI: 10.14309/ctg.0000000000000194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zagari RM, Frazzoni L, Marasco G, Fuccio L, Bazzoli F. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med 2021;112:281-7. [PMID: 32700868 DOI: 10.23736/S0026-4806.20.06810-X] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Terapevticheskii arkhiv 2017;89:5-12. [DOI: 10.17116/terarkh20178985-12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
14 Cho J, Prashar A, Jones NL, Moss SF. Helicobacter pylori Infection. Gastroenterol Clin North Am 2021;50:261-82. [PMID: 34024441 DOI: 10.1016/j.gtc.2021.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 2018;14:111-7. [DOI: 10.1016/j.jgar.2018.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
16 Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
17 Yurenev GL, Partzvania-vinogradova EV, Andreev DN, Dicheva DT, Maiev IV. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Terapevticheskii arkhiv 2018;90:33-9. [DOI: 10.26442/terarkh201890833-39] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Georgopoulos SD, Michopoulos S, Rokkas T, Apostolopoulos P, Giamarellos E, Kamberoglou D, Mentis A, Triantafyllou K. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol 2020;33:105-24. [PMID: 32127732 DOI: 10.20524/aog.2020.0446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Luo L, Ji Y, Yu L, Huang Y, Liang X, Graham DY, Lu H. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Dig Dis Sci 2020;65:3639-46. [DOI: 10.1007/s10620-020-06115-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
20 Maioli ME, Frange RFN, Grion CMC, Delfino VDA. Helicobacter pylori eradication in renal transplant candidates. J Bras Nefrol 2022:S0101-28002022005001401. [PMID: 35014666 DOI: 10.1590/2175-8239-JBN-2021-0097] [Reference Citation Analysis]
21 Mabe K, Okuda M, Kikuchi S, Amagai K, Yoshimura R, Kato M, Sakamoto N, Asaka M. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. Journal of Infection and Chemotherapy 2018;24:538-43. [DOI: 10.1016/j.jiac.2018.02.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]